Langley Porter Psychiatric Hospital
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 054144
- Received
- $69,769,161 in 3,604 records, 2025 ($7,257,255 general, $62,511,906 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 498 | $7,257,255 |
| 2025 | Research payment | 3,106 | $62,511,906 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,106 | $62,511,906 |
| Grant | 77 | $3,432,134 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 177 | $1,464,687 |
| Space rental or facility fees (teaching hospital only) | 180 | $980,228 |
| Consulting Fee | 14 | $824,729 |
| Education | 14 | $288,124 |
| Royalty or License | 19 | $120,773 |
| Long term medical supply or device loan | 8 | $92,789 |
| Gift | 4 | $33,087 |
| Charitable Contribution | 5 | $20,700 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,974,719 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients with Metastatic Castration Resistant Prostate Cancer | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,925,132 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#A phase II study of stereotactic radiosurgery in conjunction with PD-1 inhibitor Pembrolizumab for the treatm | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $296,088 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Phase Ib,II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Tri | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $125,386 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $64,367 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2025 |
| 2025-12-31 | Paragonix Technologies, Inc. | $58,773 | Research payment | Cash or cash equivalent | LungGuard Device, Pulmonology | Observational Study of Lung Preservation | 2025 |
| 2025-12-31 | PFIZER INC. | $54,686 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $54,619 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $48,857 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $37,894 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2025 |
| 2025-12-31 | PFIZER INC. | $32,798 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARM | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $30,157 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $29,889 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in F | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $29,820 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in S | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $27,711 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $21,745 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $19,869 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $18,435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $15,947 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $11,761 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2025 |
| 2025-12-31 | ABBVIE INC. | $8,251 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-12-31 | ABBVIE INC. | $7,957 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,867 | Research payment | In-kind items and services | Study to Evaluate Sampling Methods for Detection of Human Papillomavirus HPV in the Anogenital Region of Males | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,545 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2025 |
| 2025-12-31 | PFIZER INC. | $4,198 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $3,385 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2025 |
| 2025-12-31 | PFIZER INC. | $3,089 | Research payment | Cash or cash equivalent | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | 2025 | |
| 2025-12-31 | Sterilmed, Inc. | $2,604 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Merck Sharp & Dohme LLC | $2,365 | Research payment | In-kind items and services | PADCEV Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $2,036 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase II study of lenvatinib plus pembrolizumab in well differentiated G3 neuroendocrine tumors | 2025 |
| 2025-12-31 | iRhythm Technologies, Inc. | $1,420 | Research payment | In-kind items and services | ZIO XT Patch Device, Cardiology/Vascular Diseases | STUDY-Full Proof | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,216 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open Label, First in Human FIH, Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda pembrolizu | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,024 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2025 |
| 2025-12-31 | ABBVIE INC. | $600 | Research payment | In-kind items and services | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Meta | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $350 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2025 |
| 2025-12-31 | ABBVIE INC. | $295 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib with Open-Label Induction | 2025 |
| 2025-12-31 | Tanabe Pharma America, Inc. | $70 | Research payment | In-kind items and services | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon | 2025 | |
| 2025-12-31 | Alkermes, Inc. | $42 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-12-31 | ABBVIE INC. | $24 | Research payment | In-kind items and services | EPKINLY Drug, ONCOLOGY | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffus | 2025 |
| 2025-12-30 | Mirati Therapeutics, Inc. | $19,383 | Research payment | Cash or cash equivalent | KRAZATI Drug, Oncology | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutat | 2025 |
| 2025-12-30 | Daiichi Sankyo Inc. | $3,465 | Research payment | Cash or cash equivalent | DS3201-A-U202 | 2025 | |
| 2025-12-30 | Celgene Corporation | $2,025 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | Celgene Corporation | $2,025 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | Genentech, Inc. | $42,886 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Identifying ocrelizumab-resistant lymphocytes in lymphoid tissue in multiple sclerosis | 2025 |
| 2025-12-29 | Genentech, Inc. | $36,505 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | Janssen Research & Development, LLC | $9,351 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | $7,034 | Research payment | Cash or cash equivalent | Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or | 2025 | |
| 2025-12-29 | Genentech, Inc. | $2,969 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Identifying ocrelizumab-resistant lymphocytes in lymphoid tissue in multiple sclerosis | 2025 |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $15,538 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $15,538 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $13,397 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $13,397 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $13,397 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $4,033 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | KARL STORZ Endoscopy-America | $4,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $3,896 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $3,896 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $3,896 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $2,599 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $2,203 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-26 | Regeneron Pharmaceuticals, Inc. | $2,138 | Research payment | Cash or cash equivalent | A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT | 2025 | |
| 2025-12-25 | Janssen Research & Development, LLC | $10,275 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | Immunogenetic Profiling Of Guselkumab For The Treatment Of Plaque And Guttate Psoriasis | 2025 |
| 2025-12-24 | Incyte Corporation | $20,610 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and | 2025 | |
| 2025-12-24 | United Therapeutics Corporation | $15,000 | Education | Cash or cash equivalent | 2025 | ||
| 2025-12-24 | Genmab U.S., Inc. | $14,827 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,790 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,790 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,371 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | SERVIER PHARMACEUTICALS LLC | $1,056 | Research payment | Cash or cash equivalent | A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICA | 2025 | |
| 2025-12-24 | Roche TCRC, Inc. | $350 | Research payment | Cash or cash equivalent | Phase II study in early stage Parkinson s Disease Patients | 2025 | |
| 2025-12-24 | Roche TCRC, Inc. | $350 | Research payment | Cash or cash equivalent | Phase II study in early stage Parkinson s Disease Patients | 2025 | |
| 2025-12-24 | Roche TCRC, Inc. | $256 | Research payment | Cash or cash equivalent | Phase II study in early stage Parkinson s Disease Patients | 2025 | |
| 2025-12-23 | Genentech, Inc. | $106,666 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-23 | Gilead Sciences, Inc. | $98,000 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | The impact of CASB159 on the trend of PrEP uptake and HIV infection rate on a state and local level | 2025 |
| 2025-12-23 | Genentech, Inc. | $70,903 | Research payment | Cash or cash equivalent | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | 2025 | |
| 2025-12-23 | Genentech, Inc. | $22,786 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-23 | Genentech, Inc. | $22,786 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-23 | Alkermes, Inc. | $10,552 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $10,552 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $8,213 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $8,213 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $8,007 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Gilead Sciences, Inc. | $8,000 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | The impact of CASB159 on the trend of PrEP uptake and HIV infection rate on a state and local level | 2025 |
| 2025-12-23 | Alkermes, Inc. | $3,284 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $3,284 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $3,059 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-22 | Novo Nordisk AS | $553,754 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Genentech, Inc. | $45,774 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Phase 1 EIH CD19 4 1BBL | 2025 |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $14,055 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2025 |
| 2025-12-22 | Janssen Research & Development, LLC | $13,818 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | Immune Spatial Features of Guselkumab Cutaneous Response | 2025 |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $10,215 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2025 |
| 2025-12-22 | HARMONY BIOSCIENCES LLC | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $2,819 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-903 | 2025 |
| 2025-12-22 | Janssen Research & Development, LLC | $2,308 | Research payment | Cash or cash equivalent | A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Co | 2025 | |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $2,162 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-902 | 2025 |
| 2025-12-22 | Genmab A/S | $416 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2025 |
| 2025-12-19 | Genentech, Inc. | $149,390 | Research payment | Cash or cash equivalent | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | 2025 | |
| 2025-12-19 | PFIZER INC. | $38,206 | Research payment | Cash or cash equivalent | A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTI | 2025 | |
| 2025-12-19 | ARGENX US, INC. | $33,188 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $14,782 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $14,160 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $14,160 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $13,458 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | Intuitive Surgical, Inc. | $9,144 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $7,192 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $7,192 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,490 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $6,490 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | Edwards Lifesciences Corporation | $6,408 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2025 | |
| 2025-12-19 | Madrigal Pharmaceuticals | $5,742 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-12-19 | Intuitive Surgical, Inc. | $4,356 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-12-19 | ARGENX US, INC. | $3,960 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH | 2025 |
| 2025-12-19 | Hoffmann-La Roche Limited | $3,000 | Research payment | Cash or cash equivalent | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 | |
| 2025-12-19 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-19 | Madrigal Pharmaceuticals | $2,280 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $2,038 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | AstraZeneca UK Limited | $1,120 | Research payment | Cash or cash equivalent | A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Rece | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $732 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $730 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | 2025 |
| 2025-12-18 | Tanabe Pharma America, Inc. | $55,600 | Research payment | Cash or cash equivalent | Reducing diagnostic delays in erythropoietic protoporphyria using a machine learning approach | 2025 | |
| 2025-12-18 | Boston Scientific Corporation | $21,973 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-18 | BioMarin Pharmaceutical Inc. | $12,483 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-212 | 2025 |
| 2025-12-18 | Intercept Pharmaceuticals, Inc. | $7,956 | Research payment | Cash or cash equivalent | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluatin | 2025 | |
| 2025-12-18 | PFIZER INC. | $3,741 | Research payment | Cash or cash equivalent | TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT | 2025 | |
| 2025-12-18 | E.R. Squibb & Sons, L.L.C. | $2,250 | Research payment | Cash or cash equivalent | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for | 2025 | |
| 2025-12-18 | BioMarin Pharmaceutical Inc. | $565 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-212 | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-18 | PFIZER INC. | $54 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
| 2025-12-17 | Hoffmann-La Roche Limited | $55,054 | Research payment | Cash or cash equivalent | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 | |
| 2025-12-17 | Genentech, Inc. | $41,870 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | 2025 |
| 2025-12-17 | E.R. Squibb & Sons, L.L.C. | $36,341 | Research payment | Cash or cash equivalent | A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC 95266, G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)-TARGE | 2025 | |
| 2025-12-17 | SANOFI US SERVICES INC. | $11,721 | Research payment | Cash or cash equivalent | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination | 2025 | |
| 2025-12-17 | SANOFI US SERVICES INC. | $10,053 | Research payment | Cash or cash equivalent | TZIELD Biological, Endocrine & Metabolic Diseases | A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) | 2025 |
| 2025-12-17 | AtriCure, Inc. | $10,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Intuitive Surgical, Inc. | $8,766 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-12-17 | Intuitive Surgical, Inc. | $6,827 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-12-17 | Intuitive Surgical, Inc. | $6,583 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-12-17 | ABBVIE INC. | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EMBLAVEO Drug, ANTI-INFECTIVE | 2025 | |
| 2025-12-17 | JAZZ PHARMACEUTICALS INC. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-12-17 | PFIZER INC. | $2,177 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | 2025 |
| 2025-12-17 | Abbott Laboratories | $998 | Research payment | Cash or cash equivalent | MITRACLIP Device, Structural Heart | NCT04198870--MitraClip REPAIR MR Study | 2025 |
| 2025-12-16 | Gilead Sciences, Inc. | $100,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | $6,757 | Research payment | Cash or cash equivalent | A PHASE 2B, EXTENSION STUDY TO DETERMINE THE LONG-TERM SAFETY OF VEDOLIZUMAB IV IN PEDIATRIC SUBJECTS WITH ULCERATIVE CO | 2025 | |
| 2025-12-16 | Antares Pharma, Inc. | $5,436 | Research payment | Cash or cash equivalent | XYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPY | Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in M | 2025 |
| 2025-12-16 | PFIZER INC. | $4,105 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA | 2025 | |
| 2025-12-16 | Olympus America Inc. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OLYMPUS Device, Ear, Nose, Throat | 2025 | |
| 2025-12-16 | Insmed, Inc. | $2,215 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-16 | Insmed, Inc. | $2,200 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-16 | PFIZER INC. | $1,939 | Research payment | Cash or cash equivalent | TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT | 2025 | |
| 2025-12-16 | Insmed, Inc. | $1,203 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-16 | PTC Therapeutics, Inc. | $828 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | 2025 | |
| 2025-12-16 | Insmed, Inc. | $500 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-15 | UCB, Inc. | $1,454,762 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-15 | Abbott Laboratories | $124,135 | Research payment | Cash or cash equivalent | I-STAT TBI CARTRIDGE Device, Point of Care | ISM2512043A-Traumatic Brain Injury (TBI) test for diagnosis and determination of severity of brain injury in adults and | 2025 |
| 2025-12-15 | Merck Sharp & Dohme LLC | $106,695 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2025 |
| 2025-12-15 | Merck Sharp & Dohme LLC | $99,574 | Research payment | Cash or cash equivalent | STUDY NAME#Characterize initial post-acute sequelae of Covid-19 cohort using both structured and unstructured electronic | 2025 | |
| 2025-12-15 | Abbott Laboratories | $90,421 | Research payment | Cash or cash equivalent | I-STAT TBI CARTRIDGE Device, Point of Care | ISM2512043A-Traumatic Brain Injury (TBI) test for diagnosis and determination of severity of brain injury in adults and | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | $41,940 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cil | 2025 |
| 2025-12-15 | Neurocrine BioSciences, Inc. | $6,931 | Research payment | Cash or cash equivalent | CRENESSITY Drug, Neuropsychiatry | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal | 2025 |
| 2025-12-15 | PFIZER INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-15 | PFIZER INC. | $2,450 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | $1,373 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi | 2025 | |
| 2025-12-15 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-12 | Gilead Sciences, Inc. | $125,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | ABBVIE INC. | $17,979 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2025 |
| 2025-12-12 | AstraZeneca Pharmaceuticals LP | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-12 | Merck Sharp & Dohme LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-12-12 | Stryker Corporation | $696 | Research payment | Cash or cash equivalent | TORNIER PERFORM REVERSED GLENOID Device, BONE SUBSTITUTE | SHOULDER ID PRIMARY REVERSED GLENOID OUTCOMES CLINICAL STUDY (SID STUDY; UE-02-2021) | 2025 |
| 2025-12-12 | Janssen Research & Development, LLC | $184 | Research payment | Cash or cash equivalent | A Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in W | 2025 | |
| 2025-12-11 | Genentech, Inc. | $229,882 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | PFIZER INC. | $53,304 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITU | 2025 | |
| 2025-12-11 | TAIHO ONCOLOGY, INC. | $41,402 | Research payment | Cash or cash equivalent | LYTGOBI Drug, Oncology | An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $30,029 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W | 2025 | |
| 2025-12-11 | Intercept Pharmaceuticals, Inc. | $27,642 | Research payment | Cash or cash equivalent | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluatin | 2025 | |
| 2025-12-11 | ABBVIE INC. | $27,040 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-12-11 | F. Hoffmann-La Roche AG | $18,345 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-11 | PFIZER INC. | $16,555 | Research payment | Cash or cash equivalent | TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $7,552 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W | 2025 | |
| 2025-12-11 | Insmed, Inc. | $6,375 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-11 | Insmed, Inc. | $4,051 | Research payment | Cash or cash equivalent | Arikayce Drug, Respiratory | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-12-11 | Merck Sharp & Dohme LLC | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PIFELTRO Drug, INFECTIOUS DISEASE | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $3,972 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $3,938 | Research payment | Cash or cash equivalent | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, | 2025 | |
| 2025-12-11 | Stryker Corporation | $3,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | PFIZER INC. | $2,962 | Research payment | Cash or cash equivalent | AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS | 2025 | |
| 2025-12-11 | F. Hoffmann-La Roche AG | $2,921 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-11 | F. Hoffmann-La Roche AG | $1,922 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-11 | F. Hoffmann-La Roche AG | $1,597 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-11 | F. Hoffmann-La Roche AG | $1,542 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $1,426 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W | 2025 |
The latest 200 records of 3,604.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments